$KALA News

KALA Bio (KALA) Shares Soar 57% After Hours: Here's Why

KALA Bio Inks Letter Of Intent To Acquire U.S.-Based Management Services Firm For ~$15M

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team

Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Kala Bio And Virotek Finalizes Definitive Exclusive Distribution And Reseller Agreement And Related Quality, Brand, And Data Protection Agreements

Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Kala Bio Inks Letter Of Intent With Virotek To Discuss Potential Deal To Appoint Kala As Exclusive Distributor, Reseller Of Virotek;s Genetic Testing, Screening Program In U.S. For Ophthalmological Indications

Kala Bio Q2 EPS $(21.32) Up From $(85.64) YoY, Sales $0.00, Same YoY

Kala Bio Files ATM Offering Of Up To $250M In Common Stock

Kala Bio Q1 EPS $(0.14) Beats $(0.30) Estimate

KALA BIO Announces Reverse Stock Split

Kala Bio Announces 1-For-50 Reverse Stock Split, Effective May 11

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Kala Bio Q4 EPS $0.86 Beats $(1.44) Estimate, Sales $0.00

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Kala Bio Highlights Launch Of Agentic AI Platform